Diagnostic Radiography Technology Department, Faculty of Applied Medical Sciences, King Abdul-Aziz University, Saudi Arabia; Medical Image Optimisation and Perception Group (MIOPeG), Faculty of Medicine and Health, The University of Sydney, Australia.
Medical Image Optimisation and Perception Group (MIOPeG), Faculty of Medicine and Health, The University of Sydney, Australia.
Clin Imaging. 2021 Aug;76:88-97. doi: 10.1016/j.clinimag.2021.01.002. Epub 2021 Jan 12.
Mammographic density (MD) reduction is associated with lower risk of breast cancer (BC) recurrence and may be used as a marker of treatment outcome; however, trends in MD following BC therapies and the factors associated with such trends are poorly understood. The aim of this study was to investigate MD changes following BC treatment and the factors associated with these changes.
A total of 226 BC-affected patients who received BC treatments were examined. MD was assessed by the Laboratory for individualized Radiodensity Assessment (LIBRA) software. A Wilcoxon ranked signed test was used to investigate the differences in MD before and after treatment and median independent test to assess the associated factors.
Significant differences in MD between baseline and follow-up mammograms were observed for all MD measures: percent density (p ≤ 0.005), dense area (p ≤ 0.004), and nondense area (p ≤ 0.02). After adjustment, these differences were more pronounced among younger at BC diagnosis (p ≤ 0.001), premenopausal (p ≤ 0.003), and obese women (p ≤ 0.05). Changes in MD were evident regardless of the treatment regimen. MD reduction was observed among patients with high baseline MD (p < 0.001), younger at BC diagnosis (p ≤ 0.04), premenopausal (p < 0.001), and normal body mass index (p = 0.04). Patients who experienced an increase in nondense area had high percent density at baseline (p ≤ 0.001).
Two different MD changes were observed over time: MD increase and decrease. Baseline MD, menopausal status, age at BC diagnosis, and body mass index influenced these changes.
乳腺密度（MD）降低与乳腺癌（BC）复发风险降低相关，可作为治疗结果的标志物；然而，BC 治疗后 MD 的变化趋势以及与这些趋势相关的因素尚不清楚。本研究旨在调查 BC 治疗后 MD 的变化情况及其相关因素。
共纳入 226 例接受 BC 治疗的 BC 患者。MD 通过 Laboratory for individualized Radiodensity Assessment（LIBRA）软件进行评估。采用 Wilcoxon 秩和检验比较治疗前后 MD 的差异，采用中位数独立检验评估相关因素。
所有 MD 测量值（百分比密度、致密区面积和非致密区面积）的基线和随访乳房 X 线片之间的 MD 存在显著差异（p≤0.005）。调整后，在诊断为 BC 时年龄较小（p≤0.001）、绝经前（p≤0.003）和肥胖的女性中，这些差异更为明显。无论治疗方案如何，MD 都发生了变化。在基线 MD 较高（p<0.001）、诊断为 BC 时年龄较小（p≤0.04）、绝经前（p<0.001）和正常体重指数（p=0.04）的患者中观察到 MD 降低。非致密区增加的患者在基线时具有较高的百分比密度（p≤0.001）。
随着时间的推移观察到两种不同的 MD 变化：MD 增加和减少。基线 MD、绝经状态、BC 诊断时的年龄和体重指数影响这些变化。
